Status: Available

An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

The purpose of this study is to provide continued access to TPIP for participants who have successfully completed the open-label extension (OLE) studies of INS1009-203 for PAH or INS1009-212 for PH-ILD.

Trial details

Age: 18+Biological sex: AllType: Expanded AccessSponsor: Insmed IncorporatedUpdated: Jun 10, 2026

Eligibility criteria

The participant is ineligible for or cannot be treated satisfactorily with alter... [+6]

Status: Recruiting

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH). Each eligible participant will receive standard of care (SOC) plus ROC-101 for a 24-week treatment period, followed by a long-term extension period of the study through the end of the program or marketing approval/authorization.

Participants needed: 40

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: AllRock Bio, Inc.Updated: May 28, 2026Locations: 19

Eligibility criteria

Must be age 18 or older at the time of signing the informed consent form (ICF).... [+18]

Diagnosis of PH WHO Groups 2, 4, or 5 [+42]

Pulmonary Hypertension, Interstitial Lung Disease

An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)